On-chain Crude Oil TOP 1 Bear "Abraxas Capital" continues to take profit, "Short Oil Long Crypto" portfolio position weekly profit 12 million.
BlockBeats News, April 9th, according to Hyperinsight monitoring, Abraxas Capital, the largest short seller of crude oil on the Hyperliquid platform, saw a significant recovery in their two addresses in the week following the ceasefire announcement, with funds rising by over $12 million. The "short oil long crypto" portfolio position, which was previously facing a $9.7 million unrealized loss, successfully turned into a profit. As of the time of writing, the two addresses continue to take profit and reduce their positions simultaneously, with the current unrealized profit standing at $8.7 million.
After this round of profit-taking, the current total position size still remains at $152 million, with the combined short positions for U.S. and Brent crude oil totaling approximately $126 million and the long positions in the crypto market totaling around $26.1 million. Details of the crude oil short positions are as follows:
BRENTOIL Short (5x leverage): Position size reduced from $92 million to $78 million, with an average price of around $96;
WTICRUDE Short (5x leverage): Position size reduced from $51 million to $48.5 million, with an average price of around $95.
Address: 0x5b5d51203a0f9079f8aeb098a6523a13F298C060
Address: 0xb83de012dba672c76a7dbbbf3e459cb59d7d6e36
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear
Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

A recorder hidden in toilet paper exposes OpenAI's long-standing safety issues

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs
AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.
